TLE1 is a transcriptional corepressor that regulates multiple signaling pathways central to cell differentiation and oncogenic transformation. Functionally, TLE1 acts as a corepressor by binding transcription factors including those in Wnt signaling (CTNNB1/TCF), NF-κB, and FOXA2 pathways to suppress target gene expression 1. TLE1 activity is dynamically regulated through Ras-Erk pathway-mediated phosphorylation, which attenuates its repressive capacity and facilitates nuclear export, thereby allowing expression of pathway target genes 2. In disease contexts, TLE1 exhibits prominent roles in lung cancer tumorigenesis by promoting anoikis resistance through ZEB1-mediated E-cadherin repression 3, and drives acquired resistance to EGFR-targeted therapy via epithelial-mesenchymal transition in EGFR-mutant adenocarcinomas 4. TLE1 also functions in hepatocellular carcinoma where it suppresses cancer stemness by recruiting to and targeting TBX19 for degradation 5. Clinically, elevated TLE1 levels correlate with unfavorable survival outcomes in EGFR-mutant lung adenocarcinoma 4, and genetic variants near TLE1 associate with COVID-19 severity in females 6. These findings establish TLE1 as both a putative oncogenic driver and therapeutic target across multiple malignancies.